Jane Street’s SELLAS Life Sciences SLS Stock Holding History

Jane Street’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-13,800	Closed	-$153K	–	10650
2021 Q2	$153K	Buy	+13,800	New	+$135K	﹤0.01%	9037

Other funds holding SLS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Jane Street's SLS Position: Q1 2026 in Review

Jane Street sold out of SELLAS Life Sciences (SLS) in Q1 2026, closing a stake of 59,536 shares — an estimated $266K sold.

Jane Street first reported a position in SLS in Q3 2019 and held it in 10 quarters. The position peaked at $224K in Q4 2025. 160 funds tracked by Wall St. Rank hold SLS as of Q1 2026.

Jane Street reported no remaining SELLAS Life Sciences position as of Q1 2026 after selling out during the quarter.
Jane Street sold 59,536 SELLAS Life Sciences shares in Q1 2026, an estimated $266K.
Jane Street first reported a position in SELLAS Life Sciences in Q3 2019 and held it in 10 quarters.
Jane Street's SELLAS Life Sciences position peaked at $224K in Q4 2025.
160 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.